Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development
At the recent World CDx Summit, Mission Bio showcased its Tapestri platform across drug discovery and clinical development. Merck & Co. and Incyte presented new data generated using Mission Bio's Assay Services and Tapestri Platform.
Mission Bio's Chief Medical Officer Dr. Zivjena Vucetic highlighted the benefits of single-cell measurable residual disease (MRD) analysis in acute myeloid leukemia (AML). The data demonstrated a 93% sensitivity compared to 43% for flow cytometry and 71% for other molecular methods.
Mission Bio's Tapestri Platform provides a unique level of granularity and precision, essential for complex research areas such as cancer studies. Unlike traditional standard-of-care methods, Tapestri offers more tailored and effective treatment strategies by advancing the clinical utility of MRD monitoring in diseases like AML.